Trinity Biotech plc (TRIB)
USD 0.52
(-6.88%)
USD 0.52
(-6.88%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 63.73 Million USD | 23.33% |
| 2022 | 51.67 Million USD | -29.45% |
| 2021 | 73.24 Million USD | -4.89% |
| 2020 | 77.01 Million USD | 17.35% |
| 2019 | 65.62 Million USD | 27.82% |
| 2018 | 51.34 Million USD | 37.95% |
| 2017 | 37.21 Million USD | 92.01% |
| 2016 | 19.38 Million USD | 595.86% |
| 2015 | -3.9 Million USD | 57.05% |
| 2014 | -9.1 Million USD | 59.21% |
| 2013 | -22.31 Million USD | 70.22% |
| 2012 | -74.94 Million USD | -5.61% |
| 2011 | -70.96 Million USD | -22.93% |
| 2010 | -57.72 Million USD | -323.44% |
| 2009 | 25.83 Million USD | -16.64% |
| 2008 | 30.99 Million USD | -7.29% |
| 2007 | 33.43 Million USD | -30.58% |
| 2006 | 48.16 Million USD | 116.82% |
| 2005 | 22.21 Million USD | 4333.53% |
| 2004 | 501 Thousand USD | -69.61% |
| 2003 | 1.64 Million USD | -16.62% |
| 2002 | 1.97 Million USD | -57.05% |
| 2001 | 4.6 Million USD | 984.28% |
| 2000 | -520.5 Thousand USD | -105.42% |
| 1999 | 9.6 Million USD | -9.4% |
| 1998 | 10.6 Million USD | 507.69% |
| 1997 | -2.6 Million USD | 46.94% |
| 1996 | -4.9 Million USD | 33.78% |
| 1995 | -7.4 Million USD | -7300.0% |
| 1994 | -100 Thousand USD | 85.71% |
| 1993 | -700 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 88.01 Million USD | 10.22% |
| 2024 Q1 | 79.86 Million USD | 25.3% |
| 2023 Q1 | 90.51 Million USD | 75.16% |
| 2023 FY | 63.73 Million USD | 23.33% |
| 2023 Q4 | 63.73 Million USD | -19.87% |
| 2023 Q3 | 79.53 Million USD | -1.22% |
| 2023 Q2 | 80.51 Million USD | -11.05% |
| 2022 Q3 | 50.65 Million USD | 3.51% |
| 2022 Q2 | 48.93 Million USD | -26.35% |
| 2022 Q4 | 51.67 Million USD | 2.02% |
| 2022 FY | 51.67 Million USD | -29.45% |
| 2022 Q1 | 66.44 Million USD | -9.29% |
| 2021 Q1 | 51.76 Million USD | -32.78% |
| 2021 Q3 | 55.68 Million USD | 2.04% |
| 2021 Q4 | 73.24 Million USD | 31.54% |
| 2021 FY | 73.24 Million USD | -4.89% |
| 2021 Q2 | 54.57 Million USD | 5.42% |
| 2020 Q3 | 63.15 Million USD | -6.21% |
| 2020 Q1 | 68.94 Million USD | 5.05% |
| 2020 FY | 77.01 Million USD | 17.35% |
| 2020 Q2 | 67.33 Million USD | -2.33% |
| 2020 Q4 | 77.01 Million USD | 21.95% |
| 2019 FY | 65.62 Million USD | 27.82% |
| 2019 Q4 | 65.62 Million USD | 15.59% |
| 2019 Q3 | 56.77 Million USD | -0.05% |
| 2019 Q2 | 56.8 Million USD | 8.18% |
| 2019 Q1 | 52.5 Million USD | 2.27% |
| 2018 Q1 | 41.27 Million USD | 10.89% |
| 2018 Q2 | 45.75 Million USD | 10.86% |
| 2018 Q3 | 46.37 Million USD | 1.35% |
| 2018 Q4 | 51.34 Million USD | 10.72% |
| 2018 FY | 51.34 Million USD | 37.95% |
| 2017 Q1 | 25.61 Million USD | 32.13% |
| 2017 Q4 | 37.21 Million USD | 13.51% |
| 2017 Q2 | 31.26 Million USD | 22.09% |
| 2017 Q3 | 32.78 Million USD | 4.86% |
| 2017 FY | 37.21 Million USD | 92.01% |
| 2016 Q4 | 19.38 Million USD | 16.77% |
| 2016 Q1 | 3.24 Million USD | 182.99% |
| 2016 Q2 | 14.31 Million USD | 341.18% |
| 2016 Q3 | 16.6 Million USD | 15.99% |
| 2016 FY | 19.38 Million USD | 595.86% |
| 2015 Q1 | -5.74 Million USD | 36.88% |
| 2015 Q4 | -3.9 Million USD | 25.11% |
| 2015 FY | -3.9 Million USD | 57.05% |
| 2015 Q3 | -5.22 Million USD | -360.72% |
| 2015 Q2 | -1.13 Million USD | 80.28% |
| 2014 Q3 | -8.94 Million USD | 40.94% |
| 2014 Q1 | -17 Million USD | 23.79% |
| 2014 FY | -9.1 Million USD | 59.21% |
| 2014 Q2 | -15.15 Million USD | 10.91% |
| 2014 Q4 | -9.1 Million USD | -1.71% |
| 2013 Q1 | -73.09 Million USD | 2.47% |
| 2013 Q2 | -66.16 Million USD | 9.48% |
| 2013 FY | -22.31 Million USD | 70.22% |
| 2013 Q3 | -26.8 Million USD | 59.49% |
| 2013 Q4 | -22.31 Million USD | 16.75% |
| 2012 Q3 | -74.45 Million USD | -1.2% |
| 2012 Q4 | -74.94 Million USD | -0.66% |
| 2012 Q1 | -65.42 Million USD | 7.82% |
| 2012 Q2 | -73.57 Million USD | -12.45% |
| 2012 FY | -74.94 Million USD | -5.61% |
| 2011 Q2 | -71.21 Million USD | -19.54% |
| 2011 Q1 | -59.57 Million USD | -3.19% |
| 2011 Q4 | -70.97 Million USD | -0.0% |
| 2011 Q3 | -70.97 Million USD | 0.33% |
| 2011 FY | -70.96 Million USD | -22.93% |
| 2010 Q2 | -48.89 Million USD | -306.71% |
| 2010 Q1 | 23.65 Million USD | -8.45% |
| 2010 FY | -57.72 Million USD | -323.44% |
| 2010 Q4 | -57.72 Million USD | -8.24% |
| 2010 Q3 | -53.33 Million USD | -9.07% |
| 2009 Q4 | 25.83 Million USD | -8.41% |
| 2009 Q3 | 28.2 Million USD | -5.4% |
| 2009 FY | 25.83 Million USD | -16.64% |
| 2009 Q2 | 29.82 Million USD | -5.5% |
| 2009 Q1 | 31.55 Million USD | 1.81% |
| 2008 FY | 30.99 Million USD | -7.29% |
| 2008 Q3 | 32.92 Million USD | 4.53% |
| 2008 Q4 | 30.99 Million USD | -5.85% |
| 2008 Q2 | 31.49 Million USD | -9.61% |
| 2008 Q1 | 34.84 Million USD | 4.22% |
| 2007 Q4 | 33.43 Million USD | 0.0% |
| 2007 Q2 | 30.28 Million USD | 17.55% |
| 2007 FY | 33.43 Million USD | -30.58% |
| 2007 Q1 | 25.76 Million USD | -46.5% |
| 2006 Q1 | 23.28 Million USD | 4.81% |
| 2006 FY | 48.16 Million USD | 116.82% |
| 2006 Q4 | 48.16 Million USD | 13.4% |
| 2006 Q3 | 42.47 Million USD | -13.02% |
| 2006 Q2 | 48.82 Million USD | 109.75% |
| 2005 FY | 22.21 Million USD | 4333.53% |
| 2005 Q2 | 1.39 Million USD | -68.21% |
| 2005 Q1 | 4.37 Million USD | 773.45% |
| 2005 Q4 | 22.21 Million USD | 233.91% |
| 2005 Q3 | 6.65 Million USD | 378.22% |
| 2004 FY | 501 Thousand USD | -69.61% |
| 2004 Q4 | 501 Thousand USD | -1.57% |
| 2004 Q3 | 509 Thousand USD | 106.32% |
| 2004 Q2 | -8.05 Million USD | 69.69% |
| 2004 Q1 | -26.57 Million USD | -1712.19% |
| 2003 Q1 | 2.81 Million USD | 42.59% |
| 2003 Q2 | 3.3 Million USD | 17.13% |
| 2003 FY | 1.64 Million USD | -16.62% |
| 2003 Q3 | -715 Thousand USD | -121.65% |
| 2003 Q4 | 1.64 Million USD | 330.54% |
| 2002 Q3 | 1.27 Million USD | -47.32% |
| 2002 Q2 | 2.42 Million USD | 74.03% |
| 2002 Q4 | 1.97 Million USD | 54.7% |
| 2002 Q1 | 1.39 Million USD | -69.71% |
| 2002 FY | 1.97 Million USD | -57.05% |
| 2001 Q2 | -1.46 Million USD | 10.77% |
| 2001 Q1 | -1.64 Million USD | -215.65% |
| 2001 Q4 | 4.6 Million USD | 960.32% |
| 2001 FY | 4.6 Million USD | 984.28% |
| 2001 Q3 | -535 Thousand USD | 63.51% |
| 2000 Q1 | -4.18 Million USD | -143.56% |
| 2000 FY | -520.5 Thousand USD | -105.42% |
| 2000 Q4 | -520.5 Thousand USD | 94.74% |
| 2000 Q2 | -10.94 Million USD | -161.65% |
| 2000 Q3 | -9.9 Million USD | 9.54% |
| 1999 Q4 | 9.6 Million USD | 900.32% |
| 1999 Q3 | -1.2 Million USD | 0.0% |
| 1999 Q2 | -1.2 Million USD | -20.0% |
| 1999 Q1 | -1 Million USD | -109.43% |
| 1999 FY | 9.6 Million USD | -9.4% |
| 1998 Q3 | -3.1 Million USD | -181.82% |
| 1998 Q4 | 10.6 Million USD | 441.94% |
| 1998 Q2 | -1.1 Million USD | 0.0% |
| 1998 FY | 10.6 Million USD | 507.69% |
| 1997 FY | -2.6 Million USD | 46.94% |
| 1997 Q4 | -2.6 Million USD | 0.0% |
| 1996 Q4 | -4.9 Million USD | 0.0% |
| 1996 FY | -4.9 Million USD | 33.78% |
| 1995 Q4 | -7.4 Million USD | 0.0% |
| 1995 FY | -7.4 Million USD | -7300.0% |
| 1994 FY | -100 Thousand USD | 85.71% |
| 1994 Q1 | -700 Thousand USD | 0.0% |
| 1993 FY | -700 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 261.553% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 1177.707% |
| Aspira Women's Health Inc. | -331 Thousand USD | 19355.589% |
| Biodesix, Inc. | 34.3 Million USD | -85.781% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 1199.666% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 5227.879% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 5227.879% |
| Bionano Genomics, Inc. | 34.88 Million USD | -82.719% |
| CareDx, Inc | -47.97 Million USD | 232.85% |
| Check-Cap Ltd. | -24.75 Million USD | 357.457% |
| Castle Biosciences, Inc. | -83.53 Million USD | 176.302% |
| DarioHealth Corp. | -7.54 Million USD | 944.409% |
| Exact Sciences Corporation | 1.94 Billion USD | 96.73% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 177.194% |
| Guardant Health, Inc. | 220.22 Million USD | 71.059% |
| ICON Public Limited Company | 3.56 Billion USD | 98.21% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 87.097% |
| Illumina, Inc. | 1.21 Billion USD | 94.75% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 1273.201% |
| iSpecimen Inc. | -2.14 Million USD | 3068.024% |
| Standard BioTools Inc. | 46.5 Million USD | -37.049% |
| MDxHealth SA | 18.88 Million USD | -237.495% |
| 23andMe Holding Co. | -141.37 Million USD | 145.084% |
| Medpace Holdings, Inc. | -103.32 Million USD | 161.684% |
| Myriad Genetics, Inc. | 88.1 Million USD | 27.655% |
| Mainz Biomed B.V. | 349.85 Thousand USD | -18117.833% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 2712.662% |
| NeoGenomics, Inc. | 269.19 Million USD | 76.323% |
| Neogen Corporation | 735.62 Million USD | 91.336% |
| Inotiv, Inc. | 382.14 Million USD | 83.322% |
| Natera, Inc. | -200.1 Million USD | 131.852% |
| OpGen, Inc. | 11.89 Million USD | -435.962% |
| OPKO Health, Inc. | 230.68 Million USD | 72.371% |
| Psychemedics Corporation | 334 Thousand USD | -18982.635% |
| Prenetics Global Limited | -43.33 Million USD | 247.07% |
| Prenetics Global Limited | -43.33 Million USD | 247.07% |
| Precipio, Inc. | -386 Thousand USD | 16611.917% |
| Personalis, Inc. | -8.02 Million USD | 894.515% |
| RadNet, Inc. | 1.14 Billion USD | 94.451% |
| Sera Prognostics, Inc. | -2.02 Million USD | 3252.127% |
| Sotera Health Company | 2.02 Billion USD | 96.853% |
| Neuronetics, Inc. | 2.79 Million USD | -2178.727% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 515.57% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 515.57% |
| T2 Biosystems, Inc. | 33.8 Million USD | -88.518% |
| Twist Bioscience Corporation | -192.4 Million USD | 133.127% |
| Exagen Inc. | -12.77 Million USD | 599.029% |